Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk
Launched by NYU LANGONE HEALTH · Apr 13, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a personalized program can help reduce the risk of dying from preventable causes, such as heart attacks, strokes, heavy drinking, and other health issues. The program includes support for patients to help them navigate their healthcare, personalized health benefits tailored to their needs, and compensation for health-related expenses. The goal is to see if this approach can help people improve their health and live longer.
To be part of this study, you should be between 35 and 64 years old, have a low income (around $38,000 or less per year), and have specific health risks like a high chance of heart disease or heavy alcohol use. Participants will receive guidance and support through the Health and Hospitals Corporation of New York. If you qualify and agree to participate, you'll be helping researchers understand how to better assist individuals at risk for serious health conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 35 to 64
- • 2. Low SES (≤ $38,000 annual income, based on 2019 20th percentile NYC income, adjusted for family size)
- 3. Expected mortality ≥1% per year (based on age, sex, race/ethnicity), with ≥1 of the following contributors:
- • 1. 10-year cardiovascular risk ≥10% (assessed by ASCVD risk tool)
- • 2. Heavy alcohol consumption (defined using SAMHSA binge drinking definition, drinking \>4 standard drinks for men and \>3 standard drinks for women on same occasion in past month)
- • 4. Willing to be navigated to Health and Hospitals Corporation of New York health system.
- • 5. Ability to provide written informed consent in English or Spanish
- Exclusion Criteria:
- • 1. Receives regular care elsewhere than Health and Hospitals Corporation of New York
- • 2. Already diagnosed with high mortality-condition(s) that are not included in the simulation model.
About Nyu Langone Health
NYU Langone Health is a premier academic medical center located in New York City, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, NYU Langone Health integrates cutting-edge scientific inquiry with patient-centered care, striving to develop new therapies and improve health outcomes across a wide range of medical conditions. The institution is dedicated to fostering collaboration among researchers, clinicians, and patients, ensuring rigorous adherence to ethical standards and regulatory guidelines in all clinical research initiatives. By leveraging its extensive resources and expertise, NYU Langone Health aims to contribute significantly to the advancement of medical knowledge and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Ronald S Braithwaite, Braithwaite
Principal Investigator
NYU Langone Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported